Innovations in bioprocessing have led to rapid advancements in biological therapies, positively impacting the lives of millions. One less-recent innovation, which has seen a refreshed surge in popularity, is perfusion. Perfusion bioprocessing involves exchanging fresh medium for spent medium within a bioreactor while retaining the cells, allowing for higher-cell densities and lower concentrations of waste product inside the bioreactor. This technique has many benefits—such as reduced costs, and increased productivity and quality—over traditional batch and fed-batch methods.
Although perfusion bioprocessing has been around since the 1980s, it has mostly been used by manufacturers of unstable or toxic proteins, such as hemophilic factors. This bioprocessing technique has seen a much slower uptake in other biopharmaceutical applications, primarily due to the improving performance of fed-batch processes around the same time. However, advances in automation, the improved stability of certain cell lines, and the growth of single-use technologies now make perfusion a very attractive prospect for those manufacturers interested in implementing a continuous bioprocess.
One of the most important considerations when designing a perfusion process is the medium used. With the increased volumes involved, the optimal medium can enhance the
cost and productivity benefits achieved with perfusion processes. However, a key challenge is the changing requirements at different stages of the process, with seedtrain and production necessitating different concentrations, often complicating the process with the need for multiple media. At Thermo Fisher Scientific, we recognize the importance of a perfusion medium that performs from seed-train through to continuous production. The GibcoTM High-Intensity Perfusion (HIP) CHO Medium maintains performance at a variety of dilutions, allowing for the use of one medium throughout your entire workflow.
This eBook introduces the steps to take when choosing a perfusion medium, including key considerations and evaluation, along with articles highlighting the exciting potential of large-scale continuous bioprocesses. At Thermo Fisher we are excited by the prospect of a “new age” of upstream bioprocessing that utilizes continuous manufacturing and more widely adopts the use of perfusion processes. We will maintain our support in this evolving industry by continuing to innovate, developing technologies that can accelerate your path from process development to patient.